Clinical Trial Update: Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study is evaluating CCS1477 (Inobrodib) in multiple hematologic malignancies and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hematologic Malignancies
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Inobrodib (CCS1477) (Inobrodib)

Snippet

Sponsor: CellCentric Ltd. | Conditions: Haematological Malignancy, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING